AB 18. New dilemmas in small cell lung cancer tnm clinical staging small cell lung cancer independent evaluation
Abstract

AB 18. New dilemmas in small cell lung cancer tnm clinical staging small cell lung cancer independent evaluation

Konstantinos Zarogoulidis1, Dimitrios Latsios1, Konstantinos Porpodis1, Paul Zarogoulidis1,2, Kaid Darwiche2, Nick Antoniou1, Ellada Eleftheriadou1, Efthimia Boutsikou1, Kosmas Tsakiridis3, Theodoros Kontakiotis1

1Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Pulmonary Department of Interventional Pneumology, Ruhrlandklinik, University Hospital of Essen, University of Duisburg- Essen, Essen, Germany; 3Cardiothoracic Surgery Department, Saint Luke Private Hospital, Thessaloniki, Greece

Background: Many patients with Limited Disease (LD) behave similarly to those with Extensive Disease (ED) from the prognostic point of view. On the other hand, a proportion of patients with EDSCLC behave similarly to those with LD.
Patients and methods: In this retrospective study analysis 764 patients with proven SCLC were included and managed with the same therapeutic protocols. Of these patients, 278 (36.4%) has LD, while 486 (63.6%) had ED.
Results: No statistically significant difference was observed for survival for IA and IB disease stage (P=0.254) and between IIA and IIB stage (P=0.256) according to the new TNM classification. In addition, no statistical significant difference was observed for survival between stage (IIA+IIB) and IIIA stage (P=0.951), (IIA+IIIA P=0.658) and (IIB+IIIA P=0.573). Statistical significant difference was observed for survival among the LD SCLC patients with (IA+IB), (IIA+IIB+IIA) and IIB stage (P<0.001). Similarly, statistical significance was observed for ED SCLC patients with (IIA+IIB+IIIA), IIIB and IV stage (P<0.001).
Conclusions: Stratification of SCLC patients in LD and ED, although generally satisfactory, has specific limitations, and therefore a new four stage classification for SCLC should be established.

Cite this abstract as: Zarogoulidis K, Latsios D, Porpodis K, Zarogouldis P, Darwiche K, Antoniou N, Eleftheriadou E, Boutsikou E, Tsakiridis K, Kontakiotis T. New dilemmas in small cell lung cancer tnm clinical staging small cell lung cancer independent evaluation. J Thorac Dis 2012;4(S1):AB18. DOI: 10.3978/ j.issn.2072-1439.2012.s018

Article Options

Download Citation

Share